Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

License, Clinical Trial and Sponsored Research Agreements (Tables)

License, Clinical Trial and Sponsored Research Agreements (Tables)

9 Months Ended

Sep. 30, 2018

License Agreement Disclosure [Abstract]

Research and Development Arrangement, Contract to Perform for Others [Table Text Block]

For the three and nine months ended September 30, 2018 and 2017, the Company recorded the following expense in research and development for licenses acquired:

	For the three months ended September 30,				For the nine months ended September 30,
($ in thousands)	2018		2017		2018		2017
City of Hope
Manufacturing	$	-	$	-	$	75	$	-
IL13Rα2		-		-		-		250
IV/ICV		-		-		-		125
PSCA		-		-		-		300
HER2		-		-		-		600
CS1		-		-		-		600
UCLA		-		-		-		200
Fred Hutch – CD20		-		300		-		300
St. Jude – X-SCID		1,000		-		1,000		-
Total	$	1,000	$	300	$	1,075	$	2,375

For the three and nine months ended September 30, 2018 and 2017, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:

	For the three months ended September 30,				For the nine months ended September 30,
	2018		2017		2018		2017
($ in thousands)
City of Hope	$	500	$	500	$	1,500	$	1,500
City of Hope - CD123		123		642		387		1,237
City of Hope - IL13Rα2		346		194		849		1,204
City of Hope - Manufacturing		114		-		344		-
Fred Hutch - CD20		255		88		938		88
BIDMC - CRISPR		69		-		69		-
Total	$	1,407	$	1,424	$	4,087	$	4,029